Abstract
Objective To determine the impact of MS disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to SARS-CoV-2 infection.
Methods MS patients aged 18-60 were evaluated for anti-nucleocapsid and anti-Spike RBD antibody with electro-chemiluminescence immunoassay; antibody responses to Spike protein, RBD, N-terminal domain with multiepitope bead-based immunoassays (MBI); live virus immunofluorescence-based microneutralization assay; T-cell responses to SARS-CoV-2 Spike using TruCulture ELISA; and IL-2 and IFNγ ELISpot assays. Assay results were compared by DMT class. Spearman correlation and multivariate analyses were performed to examine associations between immunologic responses and infection severity.
Results Between 1/6/2021 and 7/21/2021, 389 MS patients were recruited (mean age 40.3 years; 74% female; 62% non-White). Most common DMTs were ocrelizumab (OCR) - 40%; natalizumab - 17%, Sphingosine 1-phosphate receptor (S1P) modulators −12%; and 15% untreated. 177 patients (46%) had laboratory evidence of SARS-CoV-2 infection; 130 had symptomatic infection, 47 - asymptomatic. Antibody responses were markedly attenuated in OCR compared to other groups (p≤ 0001). T-cell responses (IFNγ were decreased in S1P (p=0.03), increased in natalizumab (p<0.001), and similar in other DMTs, including OCR. Cellular and humoral responses were moderately correlated in both OCR (r=0.45, p=0.0002) and non-OCR (r=0.64, p<0.0001). Immune responses did not differ by race/ethnicity. COVID-19 clinical course was mostly non-severe and similar across DMTs; 7% (9/130) were hospitalized.
Interpretation DMTs had differential effects on humoral and cellular immune responses to SARS-CoV-2 infection. Immune responses did not correlate with COVID-19 clinical severity in this relatively young and non-disabled group of MS patients.
Competing Interest Statement
IK served on the scientific advisory board for Biogen Idec, Genentech, Alexion, EMDSerono; received consulting fees from Roche; and received research support from Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen Idec, Serono, Genzyme, and Genentech/Roche; he receives royalties from Wolters Kluwer for 'Top 100 Diagnosis in Neurology' (co-written with Jose Biller) GJS received honoraria from BMS, Eli Lilly and Genentech, and research support from BMS, Genentech, Lupus Research Alliance, NIH-NIAMS, NIH-NIAID and NIH-NILB. MK is on the scientific advisory board for NexImmune and Genentech and received research support from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Genentech, the Mark Foundation, NIH-NIGMS and NIH-NCI. CR and RP are employees and shareholders of F. Hoffmann-La Roche. MJM reported the following potential competing interests: laboratory research and shareholder of F. Hoffmann-La Roche Ltdclinical trials contracts for vaccines or MAB vs SARS-CoV-2 with Lilly, Pfizer, and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, and Pfizer; contract funding from USG/HHS/BARDA for research specimen characterization and repository; research grant funding from USG/HHS/NIH for SARS-CoV-2 vaccine and MAB clinical trials. LZR served on the scientific advisory board for Biogen, Genentech, Celgene, and Novartis and received research support from Consortium of Multiple Sclerosis Centers; Biogen; and Genentech. MC is an employee and shareholder of Genentech, Inc. KH is a former employee of Genentech, Inc. JP is an employee of Genentech, Inc. and shareholder of F. Hoffmann-La Roche. TEB, RC, ZR, KP, SE, YY, AS have nothing to disclose.
Funding Statement
This work was supported by an unrestricted investigator-initiated grant from Genentech. Editorial assistance for the figures and tables, furnished by Sarah Nordquist, PhD, of Health Interactions, Inc, was provided by F. Hoffmann-La Roche Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of NYU Langone Health gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author emails: Ilya Kister, Ilya.Kister{at}nyulangone.org Yury Patskovsky, Yury.Patskovsky{at}nyulangone.org Ryan Curtin, Ryan.Curtin{at}nyulangone.org Jinglan Pei, pei.jinglan{at}gene.com Iryna Voloshyna, Iryna.Voloshyna{at}nyulangone.org Yogambigai Velmurugu, Velmurugu.Yogambigai{at}nyulangone.org Nyovanie, Samantha, Samantha.Nyovanie@nyulangone Mark J. Mulligan,Mark.Mulligan{at}nyulangone.org Joseph Kim, Joseph.Kim{at}nyulangone.org Ethan Tardio, Ethan.Tardio{at}nyulangone.org Zoe Rimler, Zoe.rimler{at}nyulangone.org Katherine Perdomo, Katherine.Perdomo{at}nyulangone.org Tamar E Bacon, tamar.bacon{at}nyulangone.org Lana Zhovtis Ryerson, Lana.ZhovtisRyerson{at}nyulangone.org Marie Samanovic, Marie.Samanovic-golden{at}nyulangone.org Amber Cornelius, Amber.Cornelius{at}nyulangone.org Pranil Raut, raut.pranil{at}gene.com Rosetta Pedotti, rosetta.pedotti{at}roche.com Kathleen Hawker, kathleenhawker{at}hotmail.com Catarina Raposo, catarina.raposo{at}roche.com Jessica Priest, priestj3{at}gene.com Mark Cabatingan, cabatinm{at}gene.com Ryan C. Winger, wingerr{at}gene.com
↵* Senior co-authors
Acknowledgments: This work was supported by an unrestricted investigator-initiated grant from Genentech. Editorial assistance for the figures and tables, furnished by Sarah Nordquist, PhD, of Health Interactions, Inc, was provided by F. Hoffmann-La Roche Ltd.
Disclosures:
IK served on the scientific advisory board for Biogen Idec, Genentech, Alexion, EMDSerono; received consulting fees from Roche; and received research support from Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen Idec, Serono, Genzyme, and Genentech/Roche; he receives royalties from Wolters Kluwer for ‘Top 100 Diagnosis in Neurology’ (co-written with Jose Biller)
GJS received honoraria from BMS, Eli Lilly and Genentech, and research support from BMS, Genentech, Lupus Research Alliance, NIH-NIAMS, NIH-NIAID and NIH-NILB.
MK is on the scientific advisory board for NexImmune and Genentech and received research support from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Genentech, the Mark Foundation, NIH-NIGMS and NIH-NCI.
CR and RP are employees and shareholders of F. Hoffmann-La Roche.
MJM reported the following potential competing interests: laboratory research and shareholder of F. Hoffmann-La Roche Ltdclinical trials contracts for vaccines or MAB vs SARS-CoV-2 with Lilly, Pfizer, and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, and Pfizer; contract funding from USG/HHS/BARDA for research specimen characterization and repository; research grant funding from USG/HHS/NIH for SARS-CoV-2 vaccine and MAB clinical trials.
LZR served on the scientific advisory board for Biogen, Genentech, Celgene, and Novartis and received research support from Consortium of Multiple Sclerosis Centers; Biogen; and Genentech.
MC is an employee and shareholder of Genentech, Inc.
KH is a former employee of Genentech, Inc.
JP is an employee of Genentech, Inc. and shareholder of F. Hoffmann-La Roche. TEB, RC, ZR, KP, SE, YY, AS have nothing to disclose.
Data Availability
All data produced in the present study are available upon reasonable request to the authors and review and approval by the study sponsor and collaborator.
